SCHEMBL6486675

SCHEMBL6486675

Nc1ccccc1-c1ccc(C(=O)NC2CC3CC2CN3)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.44
RAB9A P51151 5/20 0.40
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 3/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 3/20 0.37
MAPK1 P28482 2/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 1/20 0.36
CASP3 P42574 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498429 0.88 RAB9A (0.40) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL6497808 0.87 ALDH1A1 (0.54) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL6488977 0.87 ALDH1A1 (0.53) SLC9A1RAB9ANPC1SMN1; SMN2LMNA
SCHEMBL6498308 0.87 RAB9A (0.53) SLC9A1RAB9ANPC1SMN1; SMN2LMNA
SCHEMBL6497797 0.85 ALDH1A1 (0.51) SLC9A1RAB9ANPC1SMN1; SMN2LMNA
SCHEMBL6489856 0.84 ERCC5 (0.45) SLC9A1RAB9ANPC1SMN1; SMN2LMNA
SCHEMBL6486556 0.83 ALDH1A1 (0.42) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL6488018 0.83 ALDH1A1 (0.48) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL6500689 0.82 FAAH (0.47)
SCHEMBL6486920 0.81 ALDH1A1 (0.40) RAB9ANPC1SMN1; SMN2LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 SLC9A1 1193/4885RAB9A 1437/4885NPC1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.